Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.38 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.37 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13668476 | 0.74 | NR3C1 (0.40) | NR3C1PGRNR3C2ARAVPR1A | |
| SCHEMBL14218514 | 0.73 | NR4A2 (0.45) | AVPR1ACNR2NPSR1NR4A2 | |
| SCHEMBL14218550 | 0.72 | CNR2 (0.45) | AVPR1ACNR2AVPR2 | |
| SCHEMBL14218479 | 0.71 | NR4A2 (0.50) | NPSR1ALDH1A1KMT2ANR4A2 | |
| SCHEMBL14218551 | 0.70 | MEN1 (0.45) | CNR2ALDH1A1KMT2A | |
| SCHEMBL14218512 | 0.69 | HTR3E (0.35) | AVPR1ACNR2NPSR1AVPR2ALDH1A1 | |
| SCHEMBL14218513 | 0.67 | HPGD (0.45) | ALDH1A1KMT2A | |
| SCHEMBL11982194 | 0.65 | CYP2C9 (0.50) | ALDH1A1KMT2A | |
| SCHEMBL10267219 | 0.64 | CYP2C19 (0.69) | — | |
| SCHEMBL3456247 | 0.62 | AVPR2 (0.63) | AVPR1ANPSR1AVPR2ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | NOVO NORDISK A/S (DK) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108598-A1 | Pharmaceutical use of substituted amides | HSD11B1, HSD3B1, HSD11B2 | NR3C1 33/4885PGR 985/4885NR3C2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.